About Biokin
Company Founder
Innovative Pharmaceutical Company Synchronizing R&D, Production and Marketing
Innovation Being Widely Recognized
Enterprise Development Planning
Company Culture
Innovation and R&D
Innovative and Efficient R&D system
SystImmune
Baili-Bio/Baili Pharmaceutical
Clinical Dynamics
Manufacturing and Quality Control
Manufacturing System
GMP standard and quality assurance
Product and Marketing
Comprehensive Marketing System
Anesthesia
Parenteral Nutrition
Anti-Infectives
Pediatrics
Traditional Chinese Medicines
Investor Relations
Corporate Governance
Announcements and Circulars
Financial Reports
Listing Document
Promotional Materials
Investor Contacts
Contact Us
English
中文简体
中文簡體
中文简体
中文簡體
English
中文简体
中文簡體
中文简体
中文簡體
About Biokin
Company Founder
Innovative Pharmaceutical Company Synchronizing R&D, Production and Marketing
Innovation Being Widely Recognized
Enterprise Development Planning
Company Culture
Innovation and R&D
Innovative and Efficient R&D system
SystImmune
Baili-Bio/Baili Pharmaceutical
Clinical Dynamics
Manufacturing and Quality Control
Manufacturing System
GMP standard and quality assurance
Product and Marketing
Comprehensive Marketing System
Anesthesia
Parenteral Nutrition
Anti-Infectives
Pediatrics
Traditional Chinese Medicines
Investor Relations
Corporate Governance
Announcements and Circulars
Financial Reports
Listing Document
Promotional Materials
Investor Contacts
Contact Us
Financial Reports
Home
>
Investor Relations
>
Financial Reports
>
Investor Relations
Corporate Governance
Announcements and Circulars
Financial Reports
Listing Document
Promotional Materials
Investor Contacts
2024
All
2024
2024 Interim Report
1
